NYSE · Biotech stocks database
AZN (AstraZeneca PLC) stock: $186.42, $289.09B market cap, $5.71B cash, $313.00B EV, $289.12B fully diluted market cap. Lead program: olaparib (Metastatic Castration-resistant Prostate Cancer), Phase 4. Data from Fully Diluted's biotech stocks database.
The Company’s registered number is 2723534 and its registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom (Tel: +44 20 3749 5000). From February 1993 until April 1999, the Company was called Zeneca Group PLC.
Source: 20-F FY2025 via SEC EDGAR
| Cash | $5,711.0M |
|---|---|
| Debt | $29,622.0M |
| Net cash | -$23,911.0M |
| Enterprise value | $312,997.3M |
| Basic shares | 1,550.7M shares |
| Fully diluted shares | 1,550.9M shares |
| Fully diluted market cap | $289,120.3M |
| Cash per share | $3.68 |
| Quarterly burn | +$3,738.0M generated |
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Cap table as of 2025-12-31.
Loading AZN daily closes…
Durvalumab · Now - Nov 7, 2026 Now · Phase 2 · Early Small (cT1N0) Triple Negative Breast Cancer
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Now - Nov 7, 2026 Now | Durvalumab | Phase 2 | Early Small (cT1N0) Triple Negative Breast Cancer | — |
| Now - Nov 16, 2026 Now | AZD9833 | Phase 3 | ER-Positive HER2-Negative Breast Cancer | — |
| Now - Nov 20, 2026 Now | AZD2936 | Phase 2 | Non-Small-Cell Lung Carcinoma | — |
| Now - Nov 23, 2026 Now | Trastuzumab deruxtecan | Phase 3 | Gastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | — |
| Now - Nov 26, 2026 Now | AZD1390 | Phase 1 | Recurrent Glioblastoma Multiforme; Primary Glioblastoma Multiforme; Brain Neoplasms, Malignant | — |
| Now - Nov 30, 2026 Now | Laroprovstat STP | Phase 1 | Healthy Participants | — |
| Now - Dec 10, 2026 Now | AZD6234 Formulation 1 | Phase 1 | Healthy Participants | — |
| Now - Dec 16, 2026 Now | AZD1613 | Phase 1 | Healthy | — |
| Nov 7 - Dec 19 Now | Dapagliflozin | Phase 2 | Chronic Kidney Disease With High Proteinuria | — |
| Nov 9 - Dec 21 in 2d | AZD0901 | Phase 2 | Gastric Cancer; Gastroesophageal Junction Cancer | — |
| Nov 11 - Dec 23 in 4d | Durvalumab | Phase 3 | Non-Small Cell Lung Cancer | — |
| Nov 11 - Dec 23 in 4d | Durvalumab | Phase 3 | Hepatocellular Carcinoma | — |
| Nov 11 - Dec 23 in 4d | Dato-DXd | Phase 3 | Metastatic Non-small Cell Lung Cancer | — |
| Nov 11 - Dec 23 in 4d | AZD0780 | Phase 2 | Dyslipidaemia | — |
| Nov 12 - Dec 24 in 5d | Elecoglipron | Phase 1 | Healthy Participants | — |
| Nov 12 - Dec 24 in 5d | Durvalumab | Phase 1 | Resectable Hepatocellular Carcinoma; Hepatocellular Carcinoma; Hepatocellular Cancer | — |
| Nov 13 - Dec 25 in 6d | Saruparib (AZD5305) | Phase 1 | Locally Advanced or Metastatic Solid Tumor | — |
| Nov 18 - Dec 30 in 11d | AZD6489 | Phase 2 | RSV Respiratory Syncytial Virus | — |
| Dec 2, 2026 - Jan 13, 2027 in 25d | AZD3974 | Phase 1 | Healthy Participants | — |
| Dec 4, 2026 - Jan 15, 2027 in 27d | Durvalumab | Phase 2 | Carcinoma, Non-Small-Cell Lung | — |
| Dec 8, 2026 - Jan 19, 2027 in 4 wks | Volrustomig | Phase 2 | Hepatocellular Carcinoma; Biliary Tract Cancer | — |
| Dec 10, 2026 - Jan 21, 2027 in 5 wks | AZD4144 | Phase 1 | Healthy | — |
| Dec 12, 2026 - Jan 23, 2027 in 5 wks | Capivasertib | Phase 3 | Breast Cancer | — |
| Dec 23, 2026 - Feb 3, 2027 in 7 wks | Trastuzumab deruxtecan | Phase 3 | Breast Cancer; HER2-positive; Metastatic | — |
| Dec 23, 2026 - Feb 3, 2027 in 7 wks | Capivasertib | Phase 1 | Moderate Hepatic Impairment | — |
| Dec 29, 2026 - Feb 9, 2027 in 7 wks | AZD0901 | Phase 2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer | — |
| Dec 30, 2026 - Feb 10, 2027 in 8 wks | Elecoglipron Reference Formulation Dose A | Phase 1 | Healthy Participants | — |
| Jan 5 - Feb 16 in 8 wks | AZD0754 | Phase 2 | Metastatic Prostate Cancer | — |
| Jan 11 - Feb 22 in 9 wks | Durvalumab | Phase 2 | Hepatocellular Carcinoma | — |
| Jan 12 - Feb 23 in 9 wks | Acalabrutinib | Phase 2 | IgM MGUS; Waldenstrom Macroglobulinemia; Neuropathy; Peripheral | — |
| Jan 18 - Mar 1 in 10 wks | eculizumab | Phase 3 | NMOSD; Neuromyelitis Optica Spectrum Disorders | — |
| Jan 28 - Mar 11 in 12 wks | [14C]AZD4954 Oral Solution | Phase 1 | Healthy Participants | — |
| Feb 5 - Mar 19 in 13 wks | AZD4248 | Phase 1 | Chronic Kidney Disease | — |
| Feb 10 - Mar 24 in 14 wks | Durvalumab combined with S-1 | Phase 2 | Biliary Tract Cancer | — |
| Feb 11 - Mar 25 in 14 wks | Durvalumab | Phase 3 | Cancer | — |
| Feb 11 - Mar 25 in 14 wks | FPI-2053 | Phase 1 | Advanced Solid Tumor; Metastatic Colorectal Carcinoma; Head and Neck Squamous Cell Carcinoma | — |
| Feb 12 - Mar 26 in 14 wks | Gemcitabine | Phase 2 | Extrahepatic Cholangiocarcinoma; Unresectable Perihilar or Ductal CCA | — |
| Feb 15 - Mar 29 in 14 wks | AZD0780 | Phase 3 | Heterozygous Familial Hypercholesterolaemia | — |
| Feb 22 - Apr 5 in 15 wks | AZD0780 | Phase 3 | Cardiovascular Disease | — |
| Mar 1 - Apr 12 in 16 wks | Savolitinib | Phase 2 | Lung Cancer | — |
| Mar 12 - Apr 23 in 4 mo | AZD9550 | Phase 2 | Overweight and Obesity | — |
| Mar 12 - Apr 23 in 4 mo | Volrustomig | Phase 1 | Advanced Clear Cell Renal Cell Carcinoma | — |
| Mar 14 - Apr 25 in 4 mo | Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | — |
| Mar 15 - Apr 26 in 4 mo | GC012F Injection | Phase 2 | Refractory Systemic Lupus Erythematosus | — |
| Mar 18 - Apr 29 in 4 mo | AZD6234 | Phase 1 | Hepatic Impairment | — |
| Mar 24 - May 5 in 5 mo | Trastuzumab deruxtecan | Phase 2 | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | — |
| Mar 25 - May 6 in 5 mo | AZD4144 | Phase 2 | Sepsis; Acute Kidney Injury | — |
| Mar 29 - May 10 in 5 mo | Acalabrutinib | Phase 3 | Lymphoma, Mantle Cell | — |
| Apr 1 - May 13 in 5 mo | Dapagliflozin | Phase 3 | Chronic Kidney Disease With High Proteinuria | — |
| Apr 5 - May 17 in 5 mo | Osimertinib | Phase 3 | Cancer | — |
| Apr 5 - May 17 in 5 mo | acalabrutinib | Phase 3 | Diffuse Large B-Cell Lymphoma | — |
| Apr 6 - May 18 in 5 mo | Anifrolumab | Phase 3 | Lupus Nephritis | — |
| May 4 - Jun 15 in 6 mo | Trastuzumab deruxtecan | Phase 2 | Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancre; Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastr | — |
| May 12 - Jun 23 in 6 mo | AZD4360 | Phase 2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer | — |
| May 14 - Jun 25 in 6 mo | AZD7760 | Phase 2 | Staphylococcus Aureus | — |
| May 18 - Jun 29 in 6 mo | Olaparib | Phase 3 | Ovarian Cancer; Breast Cancer | — |
| May 21 - Jul 2 in 6 mo | AZD4954 | Phase 1 | Healthy Participants; Dyslipidemia | — |
| May 21 - Jul 2 in 6 mo | AZD1043 | Phase 1 | Healthy Participants; Obesity | — |
| Jun 1 - Jul 13 in 7 mo | Camizestrant | Phase 3 | Breast Cancer, Early Breast Cancer | — |
| Jun 1 - Jul 13 in 7 mo | AZD5148 | Phase 2 | Clostridioides Difficile Infection | — |
| Jun 15 - Jul 27 in 7 mo | Fluorouracil (5-FU) | Phase 2 | Gastric Cancer | — |
| Jun 16 - Jul 28 in 7 mo | AZD5492 | Phase 1 | Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathies; Rheumatoid Arthritis | — |
| Jul 3 - Aug 14 in 8 mo | AZD1613 - Part A | Phase 1 | Autosomal Dominant Polycystic Kidney Disease | — |
| Jul 9 - Aug 20 in 8 mo | Rosuvastatin 1 | Phase 3 | Hypercholesterolaemia | — |
| Jul 9 - Aug 20 in 8 mo | AZD5305 | Phase 2 | Ovarian Cancer; Breast Cancer; Pancreatic Cancer | — |
| Jul 9 - Aug 20 in 8 mo | AZD4144 | Phase 1 | Hepatic Impairment | — |
| Jul 9 - Aug 20 in 8 mo | Danicopan | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis | — |
| Jul 16 - Aug 27 in 8 mo | Elecoglipron | Phase 3 | Obesity; Overweight | — |
| Jul 19 - Aug 30 in 8 mo | Tozorakimab | Phase 2 | Asthma | — |
| Aug 11 - Sep 22 in 9 mo | Durvalumab | Phase 3 | Esophageal Squamous Cell Carcinoma | — |
| Aug 11 - Sep 22 in 9 mo | Datopotamab Deruxtecan | Phase 3 | Non-small Cell Lung Cancer | — |
| Aug 11 - Sep 22 in 9 mo | Volrustomig | Phase 2 | Metastatic Colorectal Cancer | — |
| Aug 11 - Sep 22 in 9 mo | AZD9793 Intravenous (IV) monotherapy | Phase 2 | Hepatocellular Carcinoma | — |
| Aug 11 - Sep 22 in 9 mo | T-DXd | Phase 1 | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — |
| Aug 13 - Sep 24 in 9 mo | ALXN1920 | Phase 2 | Primary Membranous Nephropathy | — |
| Aug 18 - Sep 29 in 9 mo | AZD2389 | Phase 2 | Liver Fibrosis; Hepatic Cirrhosis | — |
| Aug 20 - Oct 1 in 10 mo | AZD6234 | Phase 1 | Healthy Participants | — |
| Aug 26 - Oct 7 in 10 mo | Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | — |
| Aug 27 - Oct 8 in 10 mo | AZD5863 | Phase 2 | Gastric Cancer; Gastro-esophageal Junction Cancer; Pancreatic Ductal Adenocarcinoma | — |
| Aug 30 - Oct 11 in 10 mo | IV Rilvegostomig | Phase 1 | Advanced Solid Tumors | — |
| Sep 8 - Oct 20 in 10 mo | Dato-DXd | Phase 3 | Breast Cancer | — |
| Sep 10 - Oct 22 in 10 mo | Laroprovstat | Phase 3 | Hypercholesterolaemia | — |
| Sep 10 - Oct 22 in 10 mo | Volrustomig | Phase 2 | Non-small Cell Lung Cancer | — |
| Sep 11 - Oct 23 in 10 mo | Tremelimumab | Phase 2 | Hepatocellular Carcinoma Non-resectable; HCC | — |
| Sep 13 - Oct 25 in 10 mo | Osimertinib | Phase 3 | Non-Small Cell Lung Cancer | — |
| Sep 15 - Oct 27 in 10 mo | AZD8421 | Phase 2 | ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC) | — |
| Sep 24 - Nov 5 in 11 mo | Baxdrostat | Phase 3 | Primary Hyperaldosteronism | — |
| Sep 27 - Nov 8 in 11 mo | AZD0305 | Phase 2 | Multiple Myeloma | — |
| Oct 11 - Nov 22 in 11 mo | NT-112: Autologous, engineered T Cells targeting KRAS G12D | Phase 1 | Non-small Cell Lung Cancer; Colorectal Carcinoma; Pancreatic Ductal Adenocarcinoma | — |
| Oct 11 - Nov 22 in 11 mo | SC durvalumab | Phase 1 | Solid Tumours | — |
| Oct 25 - Dec 6 in 12 mo | AZD7760 | Phase 1 | Staphylococcus Aureus Bloodstream Infection | — |
| Nov 1 - Dec 13 in 12 mo | Dato-DXd | Phase 3 | Breast Cancer | — |
| Nov 10 - Dec 22 in 12 mo | AZD8205 | Phase 2 | Breast Cancer; Biliary Tract Carcinoma; Ovarian Cancer | — |
| Nov 11 - Dec 23 in 12 mo | Saruparib | Phase 3 | Metastatic Castration-Sensitive Prostate Cancer | — |
| Nov 12 - Dec 24 in 12 mo | Datopotamab deruxtecan (Dato-DXd) | Phase 2 | Endometrial Cancer; Gastric Cancer; Metastatic Castration-resistant Prostate Cancer | — |
| Nov 12 - Dec 24 in 12 mo | Osimertinib | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | — |
| Nov 12 - Dec 24 in 12 mo | AZD0120 | Phase 2 | Relapsed/Refractory Multiple Myeloma | — |
| Nov 12 - Dec 24 in 12 mo | Trastuzumab Deruxtecan | Phase 3 | Breast Cancer | — |
| Nov 26, 2027 - Jan 7, 2028 in 13 mo | Puxitatug Samrotecan | Phase 3 | Endometrial Cancer; Malignant Solid Tumour | — |
| Nov 26, 2027 - Jan 7, 2028 in 13 mo | AZD5335 | Phase 1 | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal | — |
| Dec 13, 2027 - Jan 24, 2028 in 13 mo | Capivasertib | Phase 3 | Locally Advanced (Inoperable) or Metastatic Breast Cancer | — |
| Dec 13, 2027 - Jan 24, 2028 in 13 mo | Datopotamab deruxtecan | Phase 3 | NSCLC | — |
| Dec 15, 2027 - Jan 26, 2028 in 13 mo | Sonesitatug Vedotin | Phase 2 | Gastroesophageal Adenocarcinoma | — |
| Dec 16, 2027 - Jan 27, 2028 in 13 mo | Tozorakimab | Phase 3 | Viral Lung Infection and Acute Respiratory Failure | — |
| Dec 17, 2027 - Jan 28, 2028 in 14 mo | AZD6793 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | — |
| Dec 24, 2027 - Feb 4, 2028 in 14 mo | AZD1163 | Phase 2 | Rheumatoid Arthritis | — |
| Dec 29, 2027 - Feb 9, 2028 in 14 mo | AZD8359 | Phase 2 | Metastatic Prostate Cancer | — |
| Jan 3 - Feb 14 in 14 mo | AZD4063 | Phase 1 | Dilated Cardiomyopathy | — |
| Jan 7 - Feb 18 in 14 mo | Volrustomig | Phase 3 | Locally Advanced Cervical Cancer | — |
| Jan 11 - Feb 22 in 14 mo | Selumetinib granule formulation | Phase 2 | Neurofibromatosis Type 1 | — |
| Jan 11 - Feb 22 in 14 mo | Rilvegostomig | Phase 2 | Gastric Cancer | — |
| Jan 12 - Feb 23 in 14 mo | Trastuzumab deruxtecan | Phase 2 | Invasive Breast Cancer; Inflammatory Breast Cancer Stage III; HER2-positive Breast Cancer | — |
| Jan 20 - Mar 2 in 15 mo | AZD0292 | Phase 2 | Bronchiectasis With Pseudomonas Aeruginosa Colonization | — |
| Jan 24 - Mar 6 in 15 mo | AZD5851 | Phase 2 | Hepatocellular Carcinoma | — |
| Jan 31 - Mar 13 in 15 mo | AZD4916 | Phase 1 | Healthy Participants | — |
| Feb 8 - Mar 21 in 15 mo | Camizestrant | Phase 2 | Advanced Breast Cancer | — |
| Feb 11 - Mar 24 in 15 mo | Fulvestrant | Phase 3 | Locally Advanced or Metastatic Breast Cancer | — |
| Feb 11 - Mar 24 in 15 mo | Acalabrutinib | Phase 2 | Mantle-cell Lymphoma | — |
| Feb 12 - Mar 25 in 15 mo | Trastuzumab Deruxtecan | Phase 2 | Breast Cancer; HER2-low Breast Cancer; Metastatic Breast Cancer | — |
| Feb 12 - Mar 25 in 15 mo | Datopotamab Deruxtecan (Dato-DXd) | Phase 1 | Hormone Receptor Positive Breast Cancer; Triple Negative Breast Cancer; Non-small Cell Lung Cancer | — |
| Feb 29 - Apr 11 in 16 mo | AZD0292 | Phase 2 | Bronchiectasis With Pseudomonas Aeruginosa Colonization | — |
| Mar 15 - Apr 26 in 16 mo | Dato-DXd | Phase 3 | Breast Cancer | — |
| Mar 20 - May 1 in 17 mo | Tezepelumab | Phase 3 | Severe Asthma | — |
| Mar 20 - May 1 in 17 mo | AZD9574 | Phase 2 | Advanced Solid Malignancies | — |
| Mar 22 - May 3 in 17 mo | baxdrostat 2mg | Phase 3 | Uncontrolled Hypertension | — |
| Mar 24 - May 5 in 17 mo | Surovatamig | Phase 2 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | — |
| Apr 2 - May 14 in 17 mo | Benralizumab | Phase 3 | Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES) | — |
| Apr 4 - May 16 in 17 mo | AZD0120 | Phase 1 | Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Rheumatoid Arthritis | — |
| Apr 6 - May 18 in 17 mo | Durvalumab | Phase 2 | Small Cell Lung Carcinoma | — |
| Apr 12 - May 24 in 17 mo | Tezepelumab | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | — |
| Apr 12 - May 24 in 17 mo | AZD4512 | Phase 2 | B-cell Non-Hodgkin Lymphoma | — |
| Apr 24 - Jun 5 in 18 mo | Volrustomig | Phase 2 | Locally Advanced Cervical Cancer | — |
| May 2 - Jun 13 in 18 mo | Osimertinib | Phase 3 | Non-small Cell Lung Cancer | — |
| May 24 - Jul 5 in 19 mo | AZD1390 | Phase 1 | Advanced Solid Malignancies | — |
| Jun 2 - Jul 14 in 19 mo | Surovatamig | Phase 2 | B-cell Non-Hodgkin Lymphoma; Follicular Lymphoma (FL); Large B-Cell Lymphoma (LBCL) | — |
| Jun 5 - Jul 17 in 19 mo | Surovatamig | Phase 2 | Primary Membranous Nephropathy | — |
| Jul 4 - Aug 15 in 20 mo | Elecoglipron | Phase 3 | Type 2 Diabetes Mellitus | — |
| Jul 4 - Aug 15 in 20 mo | Elecoglipron | Phase 3 | Type 2 Diabetes Mellitus | — |
| Jul 7 - Aug 18 in 20 mo | AZD0120 | Phase 1 | Multiple Myeloma | — |
| Jul 12 - Aug 23 in 20 mo | Tezepelumab | Phase 3 | Asthma | — |
| Jul 13 - Aug 24 in 20 mo | Temozolomide | Phase 3 | Glioblastoma | — |
| Jul 24 - Sep 4 in 21 mo | Gemcitabine | Phase 3 | Biliary Tract Cancer | — |
| Jul 26 - Sep 6 in 21 mo | AZD0120 | Phase 3 | Relapsed Refractory Multiple Myeloma | — |
| Jul 31 - Sep 11 in 21 mo | AZD0486 IV | Phase 1 | B-cell Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma | — |
| Aug 8 - Sep 19 in 21 mo | Surovatamig | Phase 1 | Rheumatoid Arthritis; Systemic Lupus Erythematosus | — |
| Aug 16 - Sep 27 in 22 mo | Elecoglipron | Phase 3 | Type 2 Diabetes Mellitus | — |
| Aug 24 - Oct 5 in 22 mo | Elecoglipron | Phase 3 | Type 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease | — |
| Aug 25 - Oct 6 in 22 mo | Elecoglipron | Phase 3 | Type 2 Diabetes Mellitus | — |
| Sep 11 - Oct 23 in 22 mo | Elecoglipron | Phase 3 | Weight Management | — |
| Sep 11 - Oct 23 in 22 mo | Durvalumab | Phase 2 | Advanced Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8 | — |
| Sep 12 - Oct 24 in 22 mo | trastuzumab derxutecan | Phase 2 | Breast Cancer Metastatic; Breast Cancer Stage IV | — |
| Sep 14 - Oct 26 in 23 mo | AZD9592 | Phase 1 | Advanced Solid Tumours; Carcinoma Non-small Cell Lung; Head and Neck Neoplasms | — |
| Sep 15 - Oct 27 in 23 mo | Torvutatug samrotecan | Phase 2 | Ovarian Cancer; Lung Adenocarcinoma; Endometrial Cancer | — |
| Sep 20 - Nov 1 in 23 mo | AZD6234 | Phase 3 | Obesity or Overweight; Weight-Related Comorbidity; With/Without Diabetes Mellitus, Type 2 | — |
| Sep 20 - Nov 1 in 23 mo | AZD6234 | Phase 3 | Obesity or Overweight; Diabetes Mellitus, Type 2 | — |
| Sep 22 - Nov 3 in 23 mo | AZD6234 | Phase 3 | Obesity or Overweight | — |
| Oct 6 - Nov 17 in 23 mo | Anifrolumab | Phase 3 | Lupus Erythematosus, Systemic | — |
| Oct 26 - Dec 7 in 24 mo | AZD8965 low dose | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | — |
| Nov 7 - Dec 19 in 24 mo | Torvutatug samrotecan | Phase 3 | Platinum-sensitive Relapsed Epithelial Ovarian Cancer; Platinum-sensitive Relapsed Fallopian Tube Cancer; Platinum-sensitive Relapsed Primary Peritoneal Cancer | — |
| Nov 16 - Dec 28 in 25 mo | Anifrolumab | Phase 3 | Systemic Lupus Erythematosus | — |
| Nov 22, 2028 - Jan 3, 2029 in 25 mo | AZD0120 | Phase 3 | Newly Diagnosed Multiple Myeloma (NDMM) | — |
| Dec 1, 2028 - Jan 12, 2029 in 25 mo | AZD2962 | Phase 1 | Haematologic Neoplasms | — |
| Dec 12, 2028 - Jan 23, 2029 in 26 mo | Durvalumab | Phase 3 | Carcinoma, Non-Small-Cell Lung | — |
| Dec 12, 2028 - Jan 23, 2029 in 26 mo | Durvalumab | Phase 3 | Urinary Bladder Neoplasms; Immune Checkpoint Inhibitors; Methotrexate | — |
| Dec 12, 2028 - Jan 23, 2029 in 26 mo | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma (MCL) | — |
| Dec 28, 2028 - Feb 8, 2029 in 26 mo | Volrustomig | Phase 3 | Unresectable Pleural Mesothelioma | — |
| Dec 29, 2028 - Feb 9, 2029 in 26 mo | AZD5335 | Phase 3 | Epithelial Ovarian Cancer | — |
| Jan 1 - Feb 12 in 26 mo | Dato-DXd | Phase 3 | Breast Cancer | — |
| Jan 11 - Feb 22 in 27 mo | Durvalumab | Phase 3 | Advanced or Recurrent Endometrial Cancer | — |
| Jan 11 - Feb 22 in 27 mo | Volrustomig | Phase 2 | Sub-study 1 Cervical Cancer (Volrustomig Monotherapy); Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monothe; Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Comb | — |
| Jan 15 - Feb 26 in 27 mo | AZD3470 | Phase 2 | Advanced Solid Tumors That Are MTAP Deficient | — |
| Jan 23 - Mar 6 in 27 mo | AZD0120 - Regimen 1 | Phase 1 | Multiple Sclerosis | — |
| Feb 9 - Mar 23 in 28 mo | Tozorakimab Dose Regimen 1 | Phase 3 | Chronic Obstructive Pulmonary Disease; COPD | — |
| Feb 11 - Mar 25 in 28 mo | Durvalumab (Cohort 1-3) | Phase 2 | Urothelial Carcinoma; Bladder Cancer | — |
| Feb 11 - Mar 25 in 28 mo | Trastuzumab Deruxtecan | Phase 1 | Recurrent or Metastatic Solid Tumors | — |
| Feb 13 - Mar 27 in 28 mo | Rilvegostomig | Phase 3 | Biliary Tract Cancer | — |
| Feb 15 - Mar 29 in 28 mo | Tarlatamab | Phase 3 | Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer | — |
| Feb 22 - Apr 5 in 28 mo | AZD0120 | Phase 3 | Newly Diagnosed Multiple Myeloma | — |
| Mar 1 - Apr 12 in 28 mo | AZD0516 | Phase 2 | Metastatic Prostate Cancer | — |
| Mar 2 - Apr 13 in 28 mo | Trastuzumab deruxtecan | Phase 3 | Endometrial Cancer | — |
| Mar 9 - Apr 20 in 28 mo | Anifrolumab | Phase 3 | Systemic Lupus Erythematosus | — |
| Mar 9 - Apr 20 in 28 mo | AZD9750 | Phase 2 | Prostate Cancer | — |
| Mar 12 - Apr 23 in 29 mo | Datopotamab deruxtecan (Dato-DXd) | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | — |
| Mar 20 - May 1 in 29 mo | Eplontersen | Phase 2 | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | — |
| Mar 29 - May 10 in 29 mo | AZD3632 | Phase 2 | Acute Lymphoblastic Leukaemia; Acute Myeloid Leukaemia; Higher-risk Myelodysplastic Syndromes | — |
| Apr 6 - May 18 in 29 mo | Rilvegostomig | Phase 2 | Advanced or Metastatic Non-small Cell Lung Cancer | — |
| Apr 11 - May 23 in 30 mo | Camizestrant | Phase 3 | ER-Positive HER2-Negative Breast Cancer | — |
| Apr 24 - Jun 5 in 30 mo | Tezepelumab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | — |
| Apr 24 - Jun 5 in 30 mo | Tezepelumab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | — |
| May 10 - Jun 21 in 30 mo | AZD6621 | Phase 2 | Prostate Cancer | — |
| May 18 - Jun 29 in 31 mo | Rilvegostomig | Phase 2 | Non-Small Cell Lung Cancer | — |
| May 28 - Jul 9 in 31 mo | AZD2287 | Phase 1 | Metastatic Castration-Resistant Prostate Cancer | — |
| Jun 3 - Jul 15 in 31 mo | Acalabrutinib | Phase 2 | Diffuse Large B-Cell Lymphoma | — |
| Jun 8 - Jul 20 in 31 mo | Rilvegostomig | Phase 3 | HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | — |
| Jun 12 - Jul 24 in 32 mo | AZD0120 | Phase 2 | Lupus Erythematosus, Systemic | — |
| Jun 12 - Jul 24 in 32 mo | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | — |
| Jun 12 - Jul 24 in 32 mo | Olomorasib | Phase 3 | Carcinoma, Non-Small-Cell Lung | — |
| Jun 14 - Jul 26 in 32 mo | AZD3470 | Phase 2 | Lymphoma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma | — |
| Jun 22 - Aug 3 in 32 mo | Datopotamab Deruxtecan | Phase 3 | Metastatic Non Small Cell Lung Cancer | — |
| Jul 11 - Aug 22 in 33 mo | Osimertinib | Phase 2 | Lung Cancer | — |
| Jul 13 - Aug 24 in 33 mo | Dato-DXd | Phase 3 | Urothelial Cancer; Bladder Cancer | — |
| Jul 16 - Aug 27 in 33 mo | Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) | Phase 3 | Metastatic Castration-resistant Prostate Cancer | — |
| Jul 23 - Sep 3 in 33 mo | Surovatamig | Phase 2 | Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Mantle-cell Lymphoma | — |
| Aug 11 - Sep 22 in 34 mo | Durvalumab | Phase 3 | Small Cell Lung Carcinoma | — |
| Aug 11 - Sep 22 in 34 mo | Osimertinib | Phase 2 | Non-small Cell Lung Cancer | — |
| Sep 11 - Oct 23 in 35 mo | Rilvegostomig | Phase 3 | Biliary Tract Cancer | — |
| Sep 11 - Oct 23 in 35 mo | NT-175 | Phase 1 | Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Carcinoma | — |
| Sep 12 - Oct 24 in 35 mo | Eplontersen | Phase 3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | — |
| Sep 27 - Nov 8 in 35 mo | Sonesitatug vedotin | Phase 3 | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer | — |
| Oct 15 - Nov 26 in 36 mo | Elecoglipron | Phase 3 | Heart Failure With Preserved Ejection Fraction (HFpEF); Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | — |
| Oct 26 - Dec 7 in 36 mo | Durvalumab Plus Tremelimumab | Phase 3 | Hepatocellular Carcinoma | — |
| Nov 6 - Dec 18 in 36 mo | AZD2265 (FPI-2265) | Phase 2 | Metastatic Prostate Cancer | — |
| Nov 13 - Dec 25 in 37 mo | AZD6750 | Phase 2 | Melanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma (Skin) | — |
| Dec 7, 2029 - Jan 18, 2030 in 38 mo | AZD0780 | Phase 3 | Cardiovascular Disease | — |
| Jan 28 - Mar 11 in 39 mo | Baxdrostat and dapagliflozin | Phase 3 | Heart Failure | — |
| Jan 29 - Mar 12 in 39 mo | Saruparib (AZD5305) | Phase 3 | Advanced Breast Cancer | — |
| Jan 29 - Mar 12 in 39 mo | AZD5492 | Phase 2 | B-cell Malignancies | — |
| Feb 8 - Mar 22 in 40 mo | Datopotamab Deruxtecan | Phase 3 | Non-Small Cell Lung Cancer | — |
| Feb 11 - Mar 25 in 40 mo | ABSK043 in combination with Osimertinib | Phase 2 | Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive | — |
| Feb 14 - Mar 28 in 40 mo | Benralizumab | Phase 3 | Asthma; Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilic Syndrome (HES) | — |
| Feb 28 - Apr 11 in 40 mo | Rilvegostomig | Phase 3 | Carcinoma, Non-Small Cell Lung | — |
| Mar 15 - Apr 26 in 41 mo | Durvalumab | Phase 2 | Esophagogastric Adenocarcinoma | — |
| Apr 4 - May 16 in 41 mo | Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level | Phase 3 | Hyperkalaemia | — |
| Apr 12 - May 24 in 42 mo | Capivasertib | Phase 3 | Breast Cancer; HR-positive Breast Cancer; Advanced Breast Cancer | — |
| Apr 15 - May 27 in 42 mo | Camizestrant | Phase 3 | Breast Cancer, Early Breast Cancer | — |
| Apr 15 - May 27 in 42 mo | Datopotamab Deruxtecan | Phase 3 | Metastatic Non Small Cell Lung Cancer | — |
| Apr 26 - Jun 7 in 42 mo | Tremelimumab | Phase 3 | Hepatocellular Carcinoma | — |
| May 10 - Jun 21 in 43 mo | AZD4956 | Phase 2 | Solid Tumours | — |
| May 29 - Jul 10 in 43 mo | volrustomig | Phase 3 | Locally Advanced Head and Neck Squamous Cell Carcinoma | — |
| Jun 16 - Jul 28 in 44 mo | Benralizumab | Phase 3 | Asthma | — |
| Jun 26 - Aug 7 in 44 mo | DS-1103a | Phase 1 | Advanced Solid Tumor | — |
| Jul 9 - Aug 20 in 45 mo | Durvalumab | Phase 2 | Non-small Cell Lung Cancer | — |
| Jul 13 - Aug 24 in 45 mo | Olaparib (300 mg BID) | Phase 3 | Endometrial Cancer; p53abn | — |
| Jul 13 - Aug 24 in 45 mo | Trastuzumab deruxtecan | Phase 2 | HER2-positive Early Breast Cancer | — |
| Jul 22 - Sep 2 in 45 mo | AZD0486 | Phase 3 | Large B-cell Lymphoma | — |
| Aug 12 - Sep 23 in 46 mo | Rilvegostomig | Phase 3 | Non-small Cell Lung Cancer | — |
| Aug 12 - Sep 23 in 46 mo | Dapagliflozin | Phase 3 | Renal Insufficiency, Chronic | — |
| Aug 15 - Sep 26 in 46 mo | Trastuzumab deruxtecan | Phase 3 | Advanced Breast Cancer; Metastatic Breast Cancer; HER2 Positive | — |
| Oct 23 - Dec 4 in 48 mo | Dato-DXd | Phase 3 | High-risk Muscle Invasive Urothelial Carcinoma | — |
| Nov 15 - Dec 27 in 49 mo | Elecoglipron | Phase 3 | Chronic Kidney Disease | — |
| Dec 30, 2030 - Feb 10, 2031 in 50 mo | Rilvegostomig | Phase 3 | Non-squamous Non-small Cell Lung Cancer | — |
| Apr 17 - May 29 in 54 mo | AZD4045 | Phase 2 | Relapsed or Refractory Multiple Myeloma | — |
| May 23 - Jul 4 in 55 mo | AZD5305 | Phase 2 | Metastatic Prostate Cancer | — |
| Jul 29 - Sep 9 in 58 mo | Saruparib | Phase 3 | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | — |
| Oct 10 - Nov 21 in 60 mo | Surovatamig | Phase 3 | Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmut | — |
| Jan 7 - Feb 18 in 63 mo | Surovatamig | Phase 3 | Untreated Follicular Lymphoma | — |
| May 4 - Jun 15 in 67 mo | Trastuzumab Deruxtecan | Phase 3 | Endometrial Cancer | — |
| Feb 11 - Mar 25 in 76 mo | Anifrolumab | Phase 3 | Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythem | — |
| May 12 - Jun 23 in 79 mo | Saruparib | Phase 3 | Prostate Cancer | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Per-asset detail extracted from the 20-F filed 2026-02-24. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
| Lead drug | olaparib |
|---|---|
| Lead indication | Metastatic Castration-resistant Prostate Cancer |
| Lead phase | Phase 4 |
| Active trials | 504 |
| Collaborator trials | 308 |
| Trial | Phase | Status | Role | Sponsor | BP | Condition(s) | Mgmt guide |
|---|---|---|---|---|---|---|---|
| NCT05221840 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Non-Small Cell Lung Cancer | — |
| NCT05557838 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Hepatocellular Carcinoma | — |
| NCT06417814 | Phase 3 | Recruiting | Sponsor | AZN | — | Metastatic Non-small Cell Lung Cancer | — |
| NCT06635447 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Breast Cancer | — |
| NCT06015737 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Cutaneous Lupus Erythematosus | — |
| NCT04784715 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Breast Cancer; HER2-positive; Metastatic | — |
| NCT05303532 | Phase 3 | Enrolling by invitation | Sponsor | AZN | — | Cancer | — |
| NCT07000136 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Heterozygous Familial Hypercholesterolaemia | — |
| NCT05925803 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Systemic Sclerosis; Scleroderma | — |
| NCT07000123 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Cardiovascular Disease | — |
| NCT06706817 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Chronic Rhinosinusitis With Nasal Polyps | — |
| NCT06087835 | Phase 3 | Active, not recruiting | Sponsor | AZN | — | Chronic Kidney Disease With High Proteinuria | — |
Sponsor-matched active trials from ClinicalTrials.gov (504 as sponsor, 308 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 812 active trials for AstraZeneca on ClinicalTrials.gov
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
| Fund | Shares | Q/Q change | % of portfolio | Filing |
|---|---|---|---|---|
| OrbiMed Advisors | 915,700 | +245,500 | 3.24% | 2026-08-14 |
| Sphera Biotech | 62,530 | no change | 1.70% | 2026-08-14 |
Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.